Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Karen Manion"'
Autor:
Scott R. Solomon, Asad Bashey, Karen Manion, Kathy McNatt, D G Connaghan, A M Barreras, Dawn Speckhart, Lawrence E. Morris, R H Matthews, H.K. Holland
Publikováno v:
Bone Marrow Transplantation. 45:468-475
Historically, myeloablative allogeneic hematopoietic SCT (HSCT) has required prolonged in-patient hospitalization due to the effects of mucosal toxicity and prolonged cytopenias. We explored the safety and feasibility of outpatient management of thes
Autor:
Xu Zhang, Connie A. Sizemore, Karen Manion, Stacey Brown, Asad Bashey, Lawrence E. Morris, Scott R. Solomon, H. Kent Holland
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(10)
Purpose T-cell–replete grafts from haploidentical donors using post-transplantation cyclophosphamide may represent a solution for patients who require allogeneic hematopoietic cell transplantation (alloHCT) but lack a conventional donor. We compare
Autor:
Stacey Brown, Karen Manion, H. Kent Holland, Melissa Sanacore, Lawrence E. Morris, Amaani Hussain, Xu Zhang, Connie A. Sizemore, Scott R. Solomon, Asad Bashey
Publikováno v:
Blood. 120:3030-3030
Abstract 3030 T-cell replete HLA-haploidentical transplantation using post-transplant cyclophosphamide for prevention of GVHD and graft rejection (Haplo-PTCy) has recently emerged as a valid form of alternative-donor transplantation for patients who
Autor:
Connie A. Sizemore, Melissa Sanacore, Scott R. Solomon, Lawrence E. Morris, Karen Manion, H. Kent Holland, Xu Zhang, Stacey Brown, Asad Bashey
Publikováno v:
Blood. 118:889-889
Abstract 889 Introduction: Haploidentical hematopoietic stem cell transplantation (HSCT) provides an opportunity for nearly all patients to benefit from HSCT when a human leukocyte antigen (HLA) genotypically matched donor is not available. Initial a
Autor:
Lawrence E. Morris, Stacey Brown, Scott R. Solomon, Asad Bashey, Xu Zhang, Connie A. Sizemore, H. Kent Holland, Karen Manion
Publikováno v:
Blood. 118:833-833
Abstract 833 HLA-identical siblings (MRD) or 10 of 10 HLA - A, B, C, DRB1 and DQB1 matched unrelated volunteers (MUD) are considered optimal donors for patients who may benefit from allogeneic hematopoietic cell transplantation (allo-HCT). However, m
Autor:
Connie A. Sizemore, Karen Manion, Stacey Brown, H. Kent Holland, Scott R. Solomon, Xu Zhang, Lawrence E. Morris, Asad Bashey
Publikováno v:
Blood. 118:3016-3016
Abstract 3016FN2 Introduction Hematopoietic stem cell transplantation from unrelated donors (UD) is an effective treatment for hematologic malignancies, but has been associated with relatively high rates of high non-relapsed mortality (NRM) in older
Autor:
Karen Manion, Connie A. Sizemore, Lawrence E. Morris, Asad Bashey, Scott R. Solomon, H. Kent Holland
Publikováno v:
Blood. 116:3525-3525
Abstract 3525 Total Outpatient Care for Myeloablative Unrelated Donor Hematopoietic Cell Transplantation: A Safe and Effective Alternative to Standard In-Patient Care Myeloablative unrelated donor allogeneic stem cell transplantation (UD-SCT) is asso
Autor:
Melissa Sanacore, Scott R. Solomon, Pauline Smith, Lawrence E. Morris, Asad Bashey, H. Kent Holland, Xu Zhang, Karen Manion
Publikováno v:
Blood. 116:1262-1262
Abstract 1262 Steroid-refractory acute graft versus host disease (aGVHD) is associated with a poor prognosis. Although clinical responses occur to second line therapy they are associated with high rates of infection and dismal long-term survival. Blo
Publikováno v:
Blood. 114:2272-2272
Abstract 2272 Poster Board II-249 Non-relapse mortality (NRM) remains a major obstacle to success of unrelated donor (UD) allogeneic transplantation, mostly due to the increased morbidity from graft-versus-host disease (GVHD). Unfortunately, efforts
Autor:
Pauline Smith, H. Kent Holland, Joan Mccollum, Scott R. Solomon, Karen Manion, Lawrence E. Morris, Asad Bashey
Publikováno v:
Blood. 114:3308-3308
Abstract 3308 Poster Board III-196 The use of lineage-specific chimerism studies following allotransplantation has shown that low levels of donor T-cell chimerism can be seen following some preparative regimens despite good engraftment of donor myelo